GlassScriptPhysician profile
Anne Thai
NPI 1831366798
$8,990.92
in general payments reported to CMS, 2019-2025
33 companies · $1,691 in 2025
The $1,691 reported for 2025 was more than what 75% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $857 · 2020: $318 · 2021: $1,488 · 2022: $2,157 · 2023: $1,184 · 2024: $1,295 · 2025: $1,691.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,107 · Education: $64.55.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,106.62 |
| Education | $64.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,343.59 | 2019-2025 | Rinvoq, Linzess, Skyrizi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $880.80 | 2019-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $780.01 | 2019-2025 | Entyvio |
| Janssen Biotech, INC. | $773.34 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Braintree Laboratories, INC. | $376.67 | 2021-2025 | Suflave, Sutab |
| Pfizer INC. | $359.40 | 2019-2025 | |
| Ironwood Pharmaceuticals, INC | $249.00 | 2020-2024 | Linzess |
| Celltrion USA INC. | $231.82 | 2024-2025 | Vegzelma, Zymfentra |
| Gilead Sciences, INC. | $224.97 | 2019-2025 | |
| Lilly USA, LLC | $179.37 | 2024-2025 | Omvoh |
| Nestle Healthcare Nutrition INC. | $174.87 | 2020-2023 | |
| Qol Medical, LLC | $172.68 | 2023-2025 | Sucraid, Sucraid |
| Intercept Pharmaceuticals, INC. | $148.48 | 2019-2023 | Ocaliva |
| Ferring Pharmaceuticals INC. | $138.92 | 2019-2023 | Rebyota |
| Celgene Corporation | $136.35 | 2021-2024 | Zeposia |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $120.73 | 2021-2023 | Dificid |
| Atmo Biosciences INC | $87.68 | 2025 | Atmo Biosciences |
| Madrigal Pharmaceuticals | $82.01 | 2025 | Rezdiffra |
| Vivus LLC | $79.69 | 2024-2025 | Pancreaze |
| Phathom Pharmaceuticals, INC. | $77.22 | 2024-2025 | Voquezna |
| Genzyme Corporation | $67.59 | 2023 | |
| Ardelyx, INC. | $56.14 | 2022 | |
| Boston Scientific Corporation | $36.78 | 2023 | |
| Fresenius Kabi USA, LLC | $29.17 | 2024 | Idacio |
| Redhill Biopharma INC. | $26.28 | 2022 | |
| Novo Nordisk INC | $24.71 | 2025 | Wegovy |
| Aimmune Therapeutics, INC. | $24.70 | 2025 | Zenpep |
| Ipsen Biopharmaceuticals, INC | $23.36 | 2025 | Iqirvo |
| Pentax of America, INC. | $18.35 | 2020 | |
| Endogastric Solutions, INC | $17.97 | 2023 | Esophyx |
| Daiichi Sankyo INC. | $17.29 | 2019 | |
| Allergan, INC. | $16.33 | 2019 | |
| Echosens North America, INC. | $14.65 | 2024 | Fibroscan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anne Thai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.